PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 401/06, 401/12, 405/06 C07D 409/06, 413/12, 417/12 A61K 31/445	A1	**(11) International Publication Number:** WO 94/03445 **(43) International Publication Date:** 17 February 1994 (17.02.94)

(21) International Application Number: PCT/US93/05077

(22) International Filing Date: 3 June 1993 (03.06.93)

(30) Priority data:
07/924,773 4 August 1992 (04.08.92) US

(60) Parent Application or Grant
(63) Related by Continuation
US 07/924,773 (CIP)
Filed on 4 August 1992 (04.08.92)

(71) Applicant *(for all designated States except US):* PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)* : ROSEN, Terry, J. [US/US]; 245 Grassy Hill Road, East Lyme, CT 06333 (US).

(74) Agents: RICHARDSON, Peter, C. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).

(81) Designated States: AU, CA, JP, KR, NO, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.

(54) Title: 3-BENZYLAMINO-2-PHENYL-PIPERIDINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS



(I)

(57) Abstract

The present invention relates to derivatives of formula (I). These novel compounds are useful in the treatment of inflammatory and central nervous system disorders, as well as other disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic			SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovak Republic
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	UA	Ukraine
DE	Germany	MG	Madagascar	US	United States of America
DK	Denmark	ML	Mali	UZ	Uzbekistan
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

3-BENZYLAMINO-2-PHENYL-PIPERIDINE DERIVATIVES AS SUBSTANCE P RECEPTOR ANTAGONISTS

Background of the Invention

The present invention relates to novel substituted derivatives of nitrogen containing heterocycles, pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment and prevention of inflammatory and central nervous system disorders, as well as several other disorders. The pharmaceutically active compounds of this invention are substance P receptor antagonists.

Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being named because of their prompt stimulatory action on smooth muscle tissue. More specifically, substance P is a pharmacologically active neuropeptide that is produced in mammals (having originally been isolated from gut) and possesses a characteristic amino acid sequence that is illustrated by D. F. Veber et al. in U.S. Patent No. 4,680,283. The wide involvement of substance P and other tachykinins in the pathophysiology of numerous diseases has been amply demonstrated in the art. For instance, substance P has recently been shown to be involved in the transmission of pain or migraine (see B.E.B. Sandberg et al., Journal of Medicinal Chemistry, 25, 1009 (1982)), as well as in central nervous system disorders such as anxiety and schizophrenia, in respiratory and inflammatory diseases such as asthma and rheumatoid arthritis, respectively, in rheumatic diseases such as fibrositis, and in gastrointestinal disorders and diseases of the GI tract such as ulcerative colitis and Crohn's disease, etc. (see D. Regoli in "Trends in Cluster Headache," edited by F. Sicuteri et al., Elsevier Scientific Publishers, Amsterdam, pp. 85-95 (1987)).

Quinuclidine derivatives and related compounds that exhibit activity as substance P receptor antagonists are referred to in PCT Patent Application PCT/US 89/05338, filed November 20, 1989 and United States Patent Application Serial No. 557,442, filed July 23, 1990. Similar compounds

are referred to in the PCT Application PCT/US91/02853, filed on April 25, 1991 and PCT Application PCT/US91/03369, filed on May 14, 1991.

Monocyclic piperidine compounds are referred to in European Patent Publication 0,436,334 published on July 10, 1990.

Piperidine derivatives and related heterocyclic nitrogen containing compounds that are useful as substance P antagonists are referred to in United States Patent Application Serial No. 619,361, filed November 28, 1990, United States Patent Application Serial No. 590,423, filed September 28, 1990, United States Patent Application Serial No. 717,943 filed June 20, 1991, United States Patent Application Serial No. 719,884 filed on June 21, 1991, and United States Patent Application 724,268 filed July 1, 1991.

Compounds containing a sulfur or an oxygen group at the 3 position of a nitrogen containing ring are referred to in European Patent Publications 520,555A1 published on December 12, 1992, 499,313A1 published on August 19,1992, and 528,495A1 published on Feburary 24, 1993.

Summary of the Invention

The present invention relates to compounds of the formula



I

wherein m is an integer from 1 to 8, any one of the carbon-carbon single bonds of $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{11};

w is an integer from zero to four;

x is an integer from zero to four;

y is an integer from zero to four;

z is an integer from zero to six and wherein the ring containing $(CH_2)_z$ may contain from zero to three double bonds, and one of the carbons of $(CH_2)_z$ may optionally be replaced by oxygen, sulfur or nitrogen;

R^1 is hydrogen or (C_1-C_8) alkyl optionally substituted with hydroxy, alkoxy or fluoro;

R^3 is aryl selected from phenyl, indanyl, and naphthyl; heteroaryl selected from benzothienyl, benzofuryl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, and quinolyl; or cycloalkyl having from three to seven carbon atoms, wherein one of said carbon atoms may optionally be replaced by

nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C_3-C_7)cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from halo, nitro, (C_1-C_{10})alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10})alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, amino, (C_1-C_6)-alkylamino, di(C_1-C_6)alkylamino, -C(=O)NH-(C_1-C_6)alkyl, -(C_1-C_6)alkyl-C(=O)-NH-(C_1-C_6)alkyl, phenyl, hydroxy, -NHC(=O)H, -NHC(=O)-(C_1-C_6)alkyl, hydroxy(C_1-C_6)alkyl, and (C_1-C_6)alkoxy(C_1-C_6)alkyl;

R^6 is a functionality selected from hydrogen, (C_1-C_6)straight or branched alkyl, (C_3-C_7)cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from benzothienyl, thienyl, furyl, benzofuryl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl(C_2-C_6)alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl(C_2-C_6)alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C_1-C_{10})alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10})alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_6)-alkylamino, (C_1-C_6)alkyl-O-C(=O)-, (C_1-C_6) alkyl-O-C(=O)-(C_1-C_6)alkyl, (C_1-C_6)alkyl-C(=O)-O-, (C_1-C_6)alkyl-C(=O)-



(C_1-C_6)alkyl-O-, (C_1-C_6)alkyl-C(=O)-, (C_1-C_6)alkyl-C(=O)-



(C_1-C_6)alkyl-, di-(C_1-C_6)alkylamino, -CNH-(C_1-C_6)alkyl, (C_1-C_6)-



alkyl-C(=O)-NH-(C_1-C_6)alkyl, -NHCH and -NHC-(C_1-C_6) alkyl; and wherein one of the phenyl moieties of said benzhydryl may optionally be replaced by naphthyl, thienyl, furyl or pyridyl;

R^7 is hydrogen, phenyl or (C_1-C_6)alkyl;

or R^6 and R^7, together with the carbon to which they are attached, form a saturated carbocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by oxygen, nitrogen or sulfur;

R^8 may be attached to any atom of the nitrogen containing ring having an available bonding site and R^9 may be attached to any atom of the $(CH_2)_z$ containing ring having an available bonding site or to any carbon atom of the nitrogen containing ring having an available bonding site;

R^8 and R^9 are independently selected from hydrogen, hydroxy, halo, amino, oxo (=O), cyano, hydroxy-(C_1-C_6)alkyl, (C_1-C_6)alkoxy-(C_1-C_6)alkyl, (C_1-C_6)alkylamino, di-(C_1-C_6)alkylamino, (C_1-C_6)alkoxy,



(C_1-C_6)alkyl-O-C(=O)-, (C_1-C_6)alkyl-O-C(=O)-(C_1-C_6)alkyl,



(C_1-C_6)alkyl-C(=O)-O-, (C_1-C_6)alkyl-C(=O)-(C_1-C_6)alkyl-O-,



(C_1-C_6)alkyl-C(=O)-, (C_1-C_6)alkyl-C(=O)-(C_1-C_6)alkyl-, and the functionalities set forth in the definition of R^6;

A is selected from the group consisting of CH_2, nitrogen, oxygen, sulfur and carbonyl;

G is nitrogen, oxygen or sulfur;

R^{10} is a monocyclic or bicyclic heterocycle selected from the group consisting of pyrimidinyl, benzoxazolyl, 2,3-dihydro-3-oxobenzisosulfonazol-2-yl, morpholin-1-yl, thiomorpholin-1-yl, benzofuranyl, benzothienyl, indolyl, isoindolyl, isoquinolinyl, furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, thienyl, and groups of the formulae



wherein B and D are selected from carbon, oxygen and nitrogen, and at least one of B and D is other than carbon; E is carbon or nitrogen; n is an integer from 1 to 5; any one of the carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may be optionally substituted with (C_1-C_6)alkyl or (C_2-C_6) spiroalkyl; and either any one pair of the carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may be bridged by a one or two carbon atom linkage, or any one pair of adjacent carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may form, together with from one to three carbon atoms that are not members of the carbonyl containing ring, a (C_3-C_5) fused carbocyclic ring;

R^{11} is oximino (=NOH) or one of the functionalities set forth in any of the definitions of R^6, R^8 and R^9;

with the proviso that (a) neither R^8, R^9, R^{10} nor R^{11} can form, together with the carbon to which it is attached, a ring with R^7, (b) when z is other than zero, R^9 must be attached to the $(CH_2)_z$ containing ring and R^8 and R^9 cannot be attached to the same carbon atom, (c) when both z is zero and R^8 and R^9 are attached to the same carbon atom, then either each of R^8 and R^9 is independently selected from hydrogen, fluoro, (C_1-C_6)alkyl, hydroxy-(C_1-C_6)alkyl and (C_1-C_6)alkoxy-(C_1-C_6)alkyl, or R^8 and R^9, together with the carbon to which they are attached, form a (C_3-C_6) saturated

carbocyclic ring that forms a spiro compound with the nitrogen containing ring to which they are attached, (d) when A is nitrogen, sulfur, or oxygen, m is greater than one, (e) when A is $-CH_2-$ or carbonyl, R^{10} cannot be furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, or thienyl, (f) when w is other than zero, then y is zero, the sum of w and z is less than 7, x is an integer from 0 to 2, z is an integer from 1 to 4, and wherein the ring containing $(CH_2)_z$ is a saturated ring wherein no carbon atom may be replaced by oxygen, sulfur or nitrogen, and wherein R^8 is optionally only a substituent on one of the carbon atoms of said $(CH_2)_z$.

Preferred compounds of the formula I are those wherein z is zero, G is nitrogen, and R^9 is attached to the ring to which R^6 and R^7 are attached.

Preferred compounds of the formula I are those wherein m is an integer from 4 to 6; G is nitrogen; R^3 is phenyl optionally substituted with one or two substituents, said substituents being independently selected from halo, nitro, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, amino, (C_1-C_6)-alkylamino, di(C_1-C_6)alkylamino, $-\overset{O}{\overset{\|}{C}}NH-(C_1-C_6)$alkyl, $-(C_1-C_6)$alkyl$-\overset{O}{\overset{\|}{C}}-NH-(C_1-C_6)$alkyl, phenyl, hydroxy, $-NH\overset{O}{\overset{\|}{C}}H$, $-NH\overset{O}{\overset{\|}{C}}-(C_1-C_6)$alkyl, hydroxy$(C_1-C_6)$alkyl and (C_1-C_6)alkoxy(C_1-C_6)alkyl; R^6 is phenyl, R^7 is hydrogen, and R^1 is hydrogen.

More preferred compounds of formula I are the foregoing compounds wherein x is zero to two, w, y and z are zero and R^8, R^9 and R^{11} are hydrogen.

Specific preferred compounds of the formula I are:

(2S,3S)-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(thiazol-2-yl)aminobutyl]piperidine;

(2S,3S)-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(pyrimidin-2-yl)aminobutyl]piperidine;

cis-1-[4-(benzoxazol-2-yl)aminobutyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

(2S,3S)-1-[2,3-(dihydro-3-oxobenzisosulfonazol-2-yl)butyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

cis-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(succinimido-1-yl-butyl]piperidine;

(2S,3S)-1-(5,6-carbonyldioxyhexyl)-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

Other compounds of formula I are:

[1α, 3α, 4α, 5α]-4-(5-tert-butyl-2-methoxybenzyl)amino-3-phenyl-2-[4-(thiazol-2-yl)aminobutyl]-2-azabicyclo-[3.3.0]octane;

4-(2-methoxy-5-trifluoromethoxybenzyl)amino-3-phenyl-2-[4-(pyrimidin-2-yl)aminobutyl]-2-azabicyclo[4.4.0]decane;

4-benzhydryl-3-[4-(thiazol-2-yl)aminobutyl]-5-(2-trifluoromethoxybenzyl)amino-3-azabicyclo[4.1.0]heptane;

1-(5,6-carbonyldioxyhexyl)-3-(2-cyclopropylmethoxy-5-trifluoromethoxybenzyl)amino-2-phenylpiperidine;

3-(2,4-dimethoxybenzyl)amino-2-phenyl-1-[4-(pyrimidin-2-yl)aminopentyl]pyrrolidine;

1-[4-(glutarimido-1-yl)butyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

2-benzhydryl-3-(5-cyclopropylmethoxy-2-isopropoxy)-2-[4-(thiazol-2-yl)aminobutyl]-2-azabicyclo[3.3.0]octane.

Compounds of formula I are basic in nature. The present invention, therefore, also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the basic compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate,

maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3- naphthoate)]salts.

The term "halo", as used herein, unless otherwise indicated, includes chloro, fluoro, bromo and iodo.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

The term "one or more substituents," as used herein, includes from one to the maximum number of substituents possible based on the number of available bonding sites.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from the group consisting of urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), reflux gastroesophogal disease, hypertension, anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from the group consisting of urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), reflux gastroesophogal disease, hypertension, anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition.

The present invention also relates to a pharmaceutical composition for antagonizing the effects of substance P in a mammal, including a human, comprising a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of antagonizing the effects of substance P in a mammal, including a human, comprising administering to said mammal a substance P antagonizing amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for treating or preventing a condition selected from the group consisting of urinary incontinence,

inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a condition selected from the group consisting of urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus

erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder in a mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a disorder in mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to said mammal an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder in a mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating or preventing a disorder in mammal, including a human, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to said mammal an amount of a compound of the formula I, or a

pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder.

The compounds of the formula I have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and all stereoisomers of compounds of the formula I, and mixtures thereof.

Detailed Description of the Invention

The compounds of the formula I may be prepared as described in the following reaction schemes and discussion. Unless otherwise indicated, R^1, R^3, R^6, R^7, R^8, R^9, R^{10}, R^{11}, m, w, x, y, and z in the reaction schemes and discussion that follow are defined as above.

SCHEME 1



III



I

SCHEME 2

III



II



I

SCHEME 3

III



IV



I

SCHEME 4



The starting materials of the formula III wherein B is nitrogen and w and z equal zero may be prepared as described in United States Patent Application Serial No. 619,361, filed November 28, 1990, United States Patent Application Serial No. 675,244, filed March 26, 1991, United States Patent Application Serial No. 717,943 filed on June 20, 1991 and, United States Patent Application Serial No. 719,884 filed on June 21, 1991. These applications are incorporated herein in their entirety.

The starting materials of the formula III wherein B is nitrogen, w is zero and z is other than zero may be prepared as described in United States Patent Application Serial No. 590,423, filed September 28, 1990 and, United States Patent Application Serial No. 717,943 filed on June 20, 1991. These applications are incorporated herein in their entirety.

The starting materials of the formula III wherein B is nitrogen, y is zero and w is other than zero can be prepared as described in United States Patent Application of M. Desai entitled Bridged Aza-Bicyclic Derivatives filed on May 18, 1992, which is incorporated herein by reference in its entirety.

Referring to Scheme 1, the compounds of formula III may be converted to compounds of the formula I having the same stereochemistry by reacting them with the appropriate compound of the formula R^{10}-A-$(CH_2)_m$-L, wherein L is halo,

mesylate or tosylate and wherein any one of the carbon-carbon single bonds of said $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond, and wherein any one of the carbons of said $(CH_2)_m$ may optionally be substituted with R^{11}. This reaction is typically carried out in the presence of a base such as triethylamine, lithium diisopropylamine, sodium methoxide, potassium hydroxide or potassium t-butoxide, in a polar solvent such as t-butanol, dimethyl formamide (DMF), methylene chloride or dichloroethane, at a temperature from about room temperature to about 150°C. Preferably, the

reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine.

Scheme 2 illustrates an alternative method of converting compounds of formula III into compounds of the formula I having the same stereochemistry, and in which R^{10} is a heteroaromatic group and A is selected from oxygen, nitrogen and sulfur, by first converting compounds of formula III into intermediates of formula II. These intermediates of formula II can then be converted into compounds of formula I.

Compounds of formula III are converted into compounds of formula II by reacting them with the appropriate compound of the formula $R^{13}-(CH_2)_m-L$, wherein L is halo, mesylate or tosylate and wherein one of the carbon-carbon single bonds of said $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond, and wherein one of the carbons of said $(CH_2)_m$ may optionally be substituted with R^{11}, and wherein R^{13} is amino, hydroxyl or thiol, and wherein said hydroxyl, amino and thiol groups may be optionally protected as appropriate (e.g., t-butoxy carbonyl (BOC), trifluoroacetyl, carbobenzyloxy or carboethoxy). Preferred protecting groups for the hydroxyl, amino and thiol groups are t-butyldimethylsilyl, t-butoxycarbonyl and acetyl, respectively. This reaction is typically carried out in the presence of a base such as triethylamine or potassium t-butoxide, in a polar solvent such as methylene chloride, dichloroethane, tetrahydrofuran or chloroform, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine. The reaction is generally carried out for about 0.5 to about 72 hours.

When a protecting group is present, it is then removed from the compound of formula II. For the case of a t-butoxycarbonyl protected amino group, deprotection is accomplished by reacting the protected compound of formula

II with an acid such as hydrochloric acid, trifluoroacetic acid or perchloric acid, to yield a compound of the formula II having the same stereochemistry in which the protecting group has been replaced with hydrogen. Appropriate solvents for this reaction include polar solvents such as methylene chloride, dioxane, ether or THF, preferably dioxane. A t-butyldimethylsilyl ether is cleaved by similar conditions or by using tetrabutylammonium fluoride, in tetrahydrofuran (THF). An acetyl-protected thiol is cleaved using methanolic sodium methoxide or aqueous ammonia. The deprotection reaction is typically run at a temperature from about -10°C to about 50°C, preferably about 25°C, for about 0.5 to about 24 hours.

Intermediate compounds of formula II so formed can be converted into compounds of formula I by reacting them with the appropriate monocyclic or bicyclic heterocycle of the formula R^{10}-X wherein X is halo, mesylate, or tosylate and R^{10} is defined as above. This reaction is typically carried out in the presence of a base such as triethylamine, lithium diisopropylamine, sodium methoxide, potassium hydroxide or potassium t-butoxide, in a polar solvent such as methylene chloride, t-butanol, dimethyl formamide (DMF) or dichloroethane, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine.

Alternatively, compounds of formula II in which R^{13} is amino may be converted into compounds of formula I in which R^{10} is a cyclic imido group such as succinimido by treating the compound of formula II with an appropriate dicarboxylic acid, an activated derivative of a dicarboxylic acid (e.g., dihalo, mesylate or tosylate), or an anhydride. This reaction is typically carried out in a non-polar solvent such as xylene, hexanes, cyclohexane, ether, tetrahydrofuran or toluene at a temperature from 60°C to about the reflux temperature of the solvent.

Scheme 3 illustrates an alternative method of converting compounds of formula III into compounds of formula I, in which A is oxygen or nitrogen, by first treating compounds of formula III with a

compound of formula $L'-(CH_2)_m-L$, wherein L' is halo, mesylate or tosylate and L is defined as above, to give a compound of formula IV. This reaction is typically carried out in the presence of a base such as triethylamine, lithium diisopropylamine, sodium methoxide, potassium hydroxide or potassium t-butoxide, in a polar solvent such as t-butanol, dimethyl formamide (DMF), methylene chloride or dichloroethane, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine.

Compounds of formula IV may similarly be obtained by treating compounds of formula III with a compound of formula



in which the hydroxyl group may be protected as appropriate, preferably with the t-butyl dimethylsilyl group. This reaction is typically carried out in the presence of a base such as triethylamine, lithium diisopropylamine, sodium methoxide, potassium hydroxide or potassium t-butoxide, in a polar solvent such as t-butanol, dimethyl formamide (DMF), methylene chloride or dichloroethane, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine. After this initial reaction, the hydroxyl group can then be deprotected, if necessary, by any of the conventional means. Preferably, when the protecting group is t-butyldimethylsilyl, deprotection is carried out with tetrabutylammonium fluoride in tetrahydrofuran or with an acid such as hydrochloric acid (HCl) or acetic acid in a

polar solvent such as water or tetrahydrofuran, at a temperature from about 0°C to about 60°C, preferably at about room temperature. The free hydroxyl can then be converted into a leaving group by any of the conventional means. Treatment of the hydroxyl group with an agent such as methanesulfonyl chloride is preferred.

Compounds of formula IV are converted into compounds of formula I by reacting them with the appropriate compound of the formula R^{10}-A-H. This reaction is typically carried out in the presence of a base such as triethylamine or potassium t-butoxide, in a polar solvent such as methylene chloride, dichloroethane, tetrahydrofuran or chloroform, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine. The reaction is generally carried out for about 0.5 to about 72 hours.

Alternatively, compounds of formula IV are converted into compounds of formula I by reacting them with the corresponding anion derived from treatment of R^{10}-A-H with a base. Preferably, the anion can be formed with a reagent such as sodium hydride or butyl lithium in a solvent such as tetrahydrofuran or ether. This reaction is typically carried out in the presence of a base such as triethylamine, lithium diisopropylamine, sodium methoxide, potassium hydroxide or potassium t-butoxide, in a polar solvent such as methylene chloride, t-butanol, dimethyl formamide (DMF) or dichloroethane, at a temperature from about room temperature to about 150°C. Preferably, the reaction is carried out at the reflux temperature in methylene chloride in the presence of triethylamine.

Compounds of formula III may also be converted into the corresponding compounds of the formula I by first reacting them with the appropriate compound of the formula



wherein L is defined as above or is imidazole, and then reducing the resulting amide. This reaction is typically carried out in an inert solvent such as THF or dichloromethane at a temperature from about -20°C to about 60°C. It is preferably carried out in dichloromethane at about 0°C. Reduction of the resulting amide is accomplished by treatment with a reducing agent such as borane dimethylsulfide complex, lithium aluminum hydride or diisobutylaluminum hydride in an inert solvent such as ethyl ether or THF. The reaction temperature may range from about 0°C to about 60°C. Preferably, the reduction is accomplished using borane dimethylsulfide complex in THF at about 60°C.

Scheme 4 illustrates a method of preparing compounds of formula III wherein G is sulfur or oxygen, and R^1 is absent.

Compounds of formula III can be prepared from esters of formula VI wherein R^{12} is (C_1-C_4)alkyl or phenyl and the ring nitrogen adjacent to R^6 and R^7 is protected with an appropriate protecting group P.

Esters of formula VI are hydrolyzed to form acids of formula VI, wherein R^{12} is hydrogen, by methods well known to those skilled in the art, for example, by treatment of the ester of formula VI with an acid or a base in a solvent such as water.

The acids of formula VI, wherein R^{12} is hydrogen, are oxidized to form a compound of formula V wherein G is oxygen by reacting the compound of formula VI with lead tetraacetate in an inert solvent such as cyclohexane, hexane, methylene chloride, or benzene at a temperature of 0°C to a temperature of 90°C. Preferably, the oxidation of the compounds of formula is facilitated by the addition of copper (II) salts such as copper (II) acetate ($Cu(OCOCH_3)_2$) and pyridine.

The compound of formula V wherein G is oxygen is converted to a compound of formula III wherein R^1 is absent by alkylating the compound of formula V with a compound of formula R^3CH_2X and a base, wherein X is a leaving group

selected from halo and $-SO_3R^{12}$, wherein R^{12} is (C_1-C_4)alkyl or phenyl, and R^3 is defined as above. The reaction of the compound of formula III with the compound of formula R^3CH_2X is typically carried out in a solvent such as dichloromethane, chloroform, carbon tetrachloride, ether, hexane, cyclohexane or tetrahydrofuran, preferably tetrahydrofuran, at a temperature from about 0°C to about 60°C, preferably at about 25°C. Suitable bases include sodium hydride, organolithium bases such as butyl lithium, alkali metal alkoxides such as potassium or sodium t-butoxide and organic bases such as triethylamine, diisopropylethylamine and hexamethyldisilazide. Non-nucleophilic bases such as triethylamine, diisopropylethylamine and hexamethyldisilazide are preferred because they will not react with the compound of formula II and this will not form the unwanted byproducts that result from such reaction.

Preferably, the conversion of the compound of formula V to the compound of formula III is facilitated by preforming the anion of formula V by the addition of a strong base such as sodium hydride.

The compound of formula III so formed is then deprotected by the procedure described above to form the free amine of formula III.

The amine of formula III can be converted to compounds of formula I by the procedures described in schemes 1 through 3 above.

Alternatively, compounds of formula V can be prepared by reducing a ketone of formula VII. Ketones of formula VII can be reduced with lithium aluminium hydride, borane dimethylsulfide in tetrahydrofuran (THF), borane in THF and sodium borohydride titanium tetrachloride. Best results are obtained using sodium borohydride in THF. The reaction may be carried out at temperatures from about -78 °C to about 80°C, and are preferably carried out at about 0 °C temperature of the solvent. Compounds of formula V so

formed may be converted to compounds of formula III as described above.

Compounds of formula III wherein G is sulfur and R^1 is absent can be formed from compounds of formula V wherein G is sulfur. Compounds of formula V wherein G is sulfur may be prepared from compounds of formula VII wherein G is oxygen by reaction with phosphorus pentasulfide (P_4S_{10}) in pyridine, followed by reduction with sodium borohydride ($NaBH_4$). The temperature during the reaction with P_4S_{10} is preferably about 90°C, but can range between about 0°C to about 110°C.

Alternatively, compounds of formula V wherein G is sulfur can be prepared from compounds of formula VII wherein the ketone of formula VII is reacted with Lawesson's reagent in the presence of a base followed by reduction with sodium borohydride. The compounds of formula V wherein G is sulfur can be converted to compounds of formula III wherein G is sulfur by reaction of the compound of formula V with a compound of the formula R^3CH_2X wherein X is a leaving group selected from halo and $-SO_3R^{12}$, R^3 is defined as above and R^{12} is (C_1-C_6)alkyl or phenyl. The reaction of the compound of formula V with a compound of formula R^3CH_2X is typically carried out in a solvent such as dichloromethane, chloroform, carbon tetrachloride, hexane, cyclohexane or tetrahydrofuran, preferably dichloromethane at a temperature from about 0°C to about 60°C, preferably at about 25°C. The compound of formula III so formed is deprotected by the methods described above.

Alternatively, compounds of formula V wherein G is oxygen may be converted to compounds of formula III by reaction of the compound of formula V with mesylchloride followed by reaction with a thiol of formula R^3CH_2SH, wherein R^3 is defined as above. The reaction of the compound of formula V with the compound of formula R^3CH_2SH is typically carried out in solvents such as dichloromethane, chloroform, carbon tetrachloride, hexane, cyclohexane or tetrahydrofuran, preferably dichloromethane at a temperature

from about 0°C to about 60°C, preferably at about 25°C. The compounds of formula III so formed can be deprotected to form compounds of formula III by the methods described above.

The compounds of formula III so formed may be converted to the final products of formula I by schemes 1 through 3, described above.

The preparation of other compounds of the formula I not specifically described in the foregoing experimental section can be accomplished using combinations of the reactions described above that will be apparent to those skilled in the art.

In each of the reactions discussed or illustrated in Schemes 1 to 4 above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e. about 1 atmosphere, is preferred as a matter of convenience.

The novel compounds of the formula I and the pharmaceutically acceptable salts thereof are useful as substance P antagonists, i.e., they possess the ability to antagonize the effects of substance P at its receptor site in mammals, and therefore they are able to function as therapeutic agents in the treatment of the aforementioned disorders and diseases in an afflicted mammal.

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the Formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are

readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.

The compounds of formula I and their pharmaceutically acceptable salts exhibit substance P receptor-binding activity and therefore are of value in the treatment and prevention of a wide variety of clinical conditions the treatment or prevention of which are effected or facilitated by a decrease in substance P mediated neurotransmission. Such conditions include urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), reflux gastroesophogal disease, hypertension, anxiety, depression or dysthymic disorders, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis. Hence, these compounds are readily adapted to therapeutic use as substance P antagonists for the control and/or treatment of any of the aforesaid clinical conditions in mammals, including humans.

The compounds of the formula I and the pharmaceutically acceptable salts thereof can be administered via either the oral, parenteral or topical routes. In general, these compounds are most desirably administered in dosages ranging

from about 5.0 mg up to about 1500 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated and the particular route of administration chosen. However, a dosage level that is in the range of about 0.07 mg to about 21 mg per kg of body weight per day is most desirably employed. Variations may nevertheless occur depending upon the species of animal being treated and its individual response to said medicament, as well as on the type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

The compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by any one of the three routes previously indicated, and such administration may be carried out in single or multiple doses. More particularly, the novel therapeutic agents of this invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabletting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration, solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments

and the like, in accordance with standard pharmaceutical practice.

The activity of the compounds of the present invention as substance P antagonists may be determined by their ability to inhibit the binding of substance P at its receptor sites in bovine caudate tissue, employing radioactive ligands to visualize the tachykinin receptors by means of autoradiography. The substance P antagonizing activity of the herein described compounds may be evaluated by using the standard assay procedure described by M. A. Cascieri et al., as reported in the Journal of Biological Chemistry, Vol. 258, p. 5158 (1983). This method essentially involves determining the concentration of the individual compound required to reduce by 50% the amount of radiolabelled substance P ligands at their receptor sites in said isolated cow tissues, thereby affording characteristic IC_{50} values for each compound tested.

In this procedure, bovine caudate tissue is removed from a -70°C freezer and homogenized in 50 volumes (w./v.) of an ice-cold 50 mM Tris (i.e., trimethamine which is 2-amino-2-hydroxymethyl-1,3-propanediol) hydrochloride buffer having a pH of 7.7. The homogenate is centrifuged at 30,000 x G for a period of 20 minutes. The pellet is resuspended in 50 volumes of Tris buffer, rehomogenized and then recentrifuged at 30,000 x G for another twenty-minute period. The pellet is then resuspended in 40 volumes of ice-cold 50 mM Tris buffer (pH 7.7) containing 2 mM of calcium chloride, 2 mM of magnesium chloride, 40 g/ml of bacitracin, 4 μg/ml of leupeptin, 2 μg of chymostatin and 200 g/ml of bovine serum albumin. This step completes the production of the tissue preparation.

The radioligand binding procedure is then carried out in the following manner, viz., by initiating the reaction via the addition of 100 μl of the test compound made up to a concentration of 1 μM, followed by the addition of 100 μl of radioactive ligand made up to a final concentration 0.5 mM and then finally by the addition of 800

μl of the tissue preparation produced as described above. The final volume is thus 1.0 ml, and the reaction mixture is next vortexed and incubated at room temperature (ca. 20°C) for a period of 20 minutes. The tubes are then filtered using a cell harvester, and the glass fiber filters (Whatman GF/B) are washed four times with 50 mM of Tris buffer (pH 7.7), with the filters having previously been presoaked for a period of two hours prior to the filtering procedure. Radioactivity is then determined in a Beta counter at 53% counting efficiency, and the IC_{50} values are calculated by using standard statistical methods.

The anti-psychotic activity of the compounds of the present invention as neuroleptic agents for the control of various psychotic disorders may be determined by a study of their ability to suppress substance P-induced or substance P agonist induced hypermotility in guinea pigs. This study is carried out by first dosing the guinea pigs with a control compound or with an appropriate test compound of the present invention, then injecting the guinea pigs with substance P or a substance P agonist by intracerebral administration via canula and thereafter measuring their individual locomotor response to said stimulus.

The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these examples.

EXAMPLE 1

(2S,3S)-3-(2-Methoxybenzyl)amino-2-phenyl-1-[4-(thiazol-2-yl)aminobutyl]piperidine Hydrochloride

In a round-bottom flask were placed 100 mg (0.27 mmol) of (2S,3S)-1-(4-aminobutyl)-3-(2-methoxybenzyl)amino-2-phenylpiperidine and 0.5 mL of water. To the system were added 57 mg (0.54 mmol) of sodium carbonate and 25 μL of 2-bromothiazole, and the mixture was heated at 60°C overnight. The mixture was heated at 80-90°C for an additional day. During this period, 0.5 mL of isopropanol and 0.5 mL of 2-bromothiazole were added to the system. The mixture was

partitioned between chloroform and saturated aqueous sodium bicarbonate and extracted with two portions of chloroform. The combined chloroform extracts were dried (Na_2SO_4) and concentrated. The crude brown oil was purified by flash column chromatography (35 g of silica gel) using 1:3 methanol/chloroform as the eluant to obtain 38 mg of product. This material was dissolved in ethyl acetate, and ether saturated with hydrogen chloride (HCl) was added to the solution. The solvent was removed with a pipet and the residue was subjected to high vacuum to obtain 21 mg of the title compound, mp 90-95°C.

^{1}H NMR ($CDCl_3$) δ 1.20 (m, 1H), 1.50 (m, 3H), 1.76 (m, 3H), 2.02 (m, 3H), 2.56 (m, 2H), 3.20 (m, 3H), 3.28 (d, 1H, J=2), 3.38 (d, 1H, J=15), 3.46 (s, 3H), 3.66 (d, 1H, J=15), 5.80 (br s, 1H), 6.39 (d, 1H, J=3), 6.60 (d, 1H, J=9), 6.70 (t, 1H, J=6), 6.81 (d, 1H, J=6), 7.04 (m, 2H), 7.26 (m, 5H). HRMS calc'd for $C_{26}H_{34}N_4OS$: 450.2457. Found: 450.2411.

EXAMPLE 2

(2S,3S)-3-(2-Methoxybenzyl)amino-2-phenyl-1-[4-(pyrimidin-2-yl)aminobutyl]piperidine Hydrochloride

The title compound was prepared in a similar manner to the compound of Example 1 by replacing 2-bromothiazole with 2-chloropyrimidine; mp 123-127°C (dec.) ^{1}H NMR ($CDCl_3$) δ 1.46 (m, 5H), 1.94 (m, 6H), 2.54 (m, 2H), 3.24 (m, 4H), 3.35 (d, 1H, J=15), 3.48 (s, 3H), 3.64 (d, 1H, J=15), 6.42 (t, 1H, J=5), 6.59 (d, 1H, J=9), 6.68 (t, 1H, J=6), 6.80 (d, 1H, J=6), 7.05 (t, 1H, J=9), 7.22 (m, 5H), 8.18 (d, 2H, J=5). HRMS calc'd for $C_{27}H_{35}N_5O$: 445.2836. Found: 445.2813.

EXAMPLE 3

cis-1-[4-(Benzoxazol-2-yl)aminobutyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine Hydrochloride

The title compound was prepared in a similar manner to the compound of Example 1 by replacing (2S, 3S)-3-(2-methoxybenzyl)amino-2-phenylpiperidine with the corresponding racemate and 2-bromothiazole with 2-chlorobenzoxazole; mp 158-160°C (dec.) ^{1}H NMR ($CDCl_3$) δ 1.58 (m, 5H), 1.90 (m, 1H), 2.04 (m, 4H), 2.20 (m, 1H), 2.56 (m,

1H), 2.71 (d, 1H, J=2), 3.25 (m, 1H), 3.38 (m, 5H), 3.57 (d, 1H, J=15), 3.96 (d, 1H, J=15), 6.60 (d, 1H, J=6), 6.76 (t, 1H, J=6), 6.96 (m, 2H), 7.12 (m, 3H), 7.28 (m, 6H). HRMS calc'd for $C_{30}H_{36}N_4O_2$: 484.2838. Found: 484.2844.

EXAMPLE 4

cis-3-(2-Methoxybenzyl)amino-1-[4-oxo-4-(thien-2-yl)butyl]-2-phenylpiperidine

Under a nitrogen atmosphere, in a round-bottom flask were placed 200 mg (0.68 mmol) of cis-3-(2-methoxybenzyl)amino-2-phenylpiperidine and 0.6 mL of tetrahydrofuran. To the system were added 95 μL of triethylamine and 0.11 mL (0.68 mmol) of 4-chloro-1-oxo-1-(thien-2-yl)butane, and the mixture was heated at 75°C for 1 day. The reaction mixture was partitioned between chloroform and saturated aqueous sodium bicarbonate and extracted with three portions of chloroform. The combined extracts were dried using sodium sulfate (Na_2SO_4) and concentrated. The crude product was purified by flash column chromotography (20 g of silica gel) using 1:19 methanol/chloroform as the eluant to obtain pure title compound as its free base. This material was dissolved in ethyl acetate, and the ether saturated with HCl was added to the solution. Filtration of the resulting suspension afforded the title compound as a hygroscopic solid, mp 69-74°C. ^{1}H NMR ($CDCl_3$) δ 1.22 (m, 1H), 1.50 (m, 2H), 2.00 (m, 5H), 2.66 (m, 3H), 2.88 (m, 1H), 3.24 (m, 1H), 3.35 (d, 1H, J=2), 3.40 (d, 1H, J=15), 3.48 (s, 3H), 3.70 (d, 1H, J=15), 6.65 (d, 1H, J=6), 6.76 (t, 1H, J=6), 6.88 (d, 1H, J=6), 7.10 (m, 2H), 7.28 (m, 4H), 7.58 (m, 1H), 7.66 (d, 1H, J=2). Mass spectrum: m/z 448 (parent).

EXAMPLE 5

(2S,3S)-1-[2,3-(Dihydro-3-oxobenzisosulfonazol-2-yl)butyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine Hydrochloride

The title compound was prepared in a similar manner to the compound of Example 4 by replacing cis-3-(2-methoxybenzylamino)-2-phenylpiperidine with the

corresponding (2S, 3S)-enantiomer and the substituted chlorobutane with 1-bromo-4-(2,3-dihydro-3-oxobenzisosulfonazol-2-yl)butane: mp 120-122°C. ^{1}H NMR ($CDCl_3$) δ 1.60 (m, 6H), 2.02 (m, 4H), 2.58 (m, 2H), 3.22 (m, 1H), 3.31 (d, 1H, J=3), 3.37 (d, 1H, J=15), 3.47 (s, 3H), 3.68 (m, 3H), 6.62 (d, 1H, J=6), 6.73 (t, 1H, J=9), 6.86 (d, 1H, J=9), 7.09 (t, 1H, J=6), 7.26 (m, 5H), 7.82 (m, 3H), 8.00 (m, 1H). HRMS calc'd for $C_{30}H_{25}N_3O_4S$: 533.2344. Found: 533.2354.

EXAMPLE 6

cis-3-(2-Methoxybenzyl)amino-2-phenyl-1-[4-succinimido-1-yl)butyl]piperidine Hydrochloride

The title compound was prepared in a similar manner to the compound of Example 4 by replacing the substituted chlorobutane with 4-(succinimido-1-yl)-1-methylsufonyloxybutane [prepared from 4-amino-1-butanol by sequential treatment with succinic anhydride (xylenes, acetic anhydride, reflux, 2 hours), sodium methoxide (methanol, 3 hours) and methanesulfonyl chloride (triethylamine, THF, 3h)]. ^{1}H NMR ($CDCl_3$) δ 1.40 (m, 4H), 1.60 (m, 1H), 1.94 (m, 1H), 1.96 (m, 2H), 2.34 (m, 1H), 2.46 (m, 1H), 2.60 (m, 4H), 3.14 (m, 1H), 3.20 (d, 1H, J=2), 3.34 (m, 6H), 3.51 (m, 1H), 3.62 (m, 2H), 6.56 (d, 1H, J=9), 6.67 (t, 1H, J=9), 6.78 (d, 1H, J=6), 7.03 (t, 1H, J=6), 7.18 (m, 5H). HRMS calc'd for $C_{27}H_{35}N_3O_3$: 449.2678. Found: 449.2678.

EXAMPLE 7

(2S,3S)-1-(5,6-Carbonyldioxyhexyl)-3-(2-methoxybenzyl)-amino-2-phenylpiperidine Hydrochloride

Under a nitrogen atmosphere, in a round-bottom flask were placed 0.15 mmol of (2S,3S)-1-(5,6-dihydroxyhexyl)-3-(2-methoxybenzyl)amino-2-phenylpiperidine and 0.5 ml of $CHCl_3$. To the system was added 49 mg (0.30 mmol) carbonyldiimidazole. The mixture was heated at 60-75°C for 5 days. During this period, additional (325 mg) carbonyldiimidazole, $CHCl_3$ (0.5 ml), and THF (0.5 ml) were added to the system. The reaction mixture was partitioned between chloroform and saturated aqueous sodium bicarbonate

and extracted with two portions of chloroform. The combined extracts were washed with water, dried (Na_2SO_4) and concentrated. The crude product was purified by flash column chromatography (1.5 g of silica gel) using 1:9 methanol/chloroform as the eluant to obtain 35 mg of product. This material was dissolved in ethyl acetate, and ether saturated with HCl was added to the solution. Solvent was removed from the resulting suspension using a pipet, and the residue was subjected to high vacuum to afford 17 mg of the title compound, mp 73-76°C (dec). ^1H NMR ($CDCl_3$) δ 1.26 (m, 2H), 1.50 (m, 4H), 1.70 (m, 2H), 1.94 (m, 1H), 2.04 (m, 3H), 2.58 (m, 2H), 3.22 (m, 1H), 3.30 (d, 1H, J=2), 3.38 (d, 1H, J=15), 3.47 (s, 3H), 3.70 (d, 1H, J=15), 4.00 (m, 1H), 4.44 (m, 1H), 4.60 (m, 1H), 6.64 (d, 1H, J=9), 6.75 (t, 1H, J=6), 6.85 (d, 1H, J=6), 7.10 (t, 1H, J=9), 7.26 (m, 5H). HRMS calc'd for $C_{23}H_{34}N_2O_4$: 438.2518. Found: 438.2521.

EXAMPLE 8

cis-3-(2-Methoxybenzyl)amino-2-phenyl-1-[4-(thien-2-yl)butyl]piperidine

The title compound was prepared in a similar manner to the compound of Example 4 by replacing the chlorobutane with 1-methylsulfonyloxy-4-(thien-2-yl)butane. ^1H NMR ($CDCl_3$) δ 1.32-1.6 (m, 6H), 1.96-2.3 (m, 4H), 2.50-2.72 (m, 4H), 2.8-2.9 (m, 1H), 3.16-3.38 (m, 3H), 3.40 (s, 3H), 3.65-3.80 (m, 1H), 6.59-6.76 (m, 3H), 6.81-6.88 (m, 2H), 7.02-7.12 (m, 2H), 7.20-7.38 (m, 5H). Mass spectrum: m/z 434 (parent).

CLAIMS

1. A compound having the formula



I

wherein m is an integer from 1 to 8, and any one of the carbon-carbon single bonds of $(CH_2)_m$ may optionally be replaced by a carbon-carbon double bond or a carbon-carbon triple bond, and any one of the carbon atoms of said $(CH_2)_m$ may optionally be substituted with R^{11};

w is an integer from zero to four;

x is an integer from zero to four;

y is an integer from zero to four;

z is an integer from one to six, wherein the ring containing $(CH_2)_z$ may contain from zero to three double bonds, and one of the carbons of $(CH_2)_z$ may optionally be replaced by oxygen, sulfur or nitrogen;

R^1 is hydrogen or (C_1-C_8) alkyl optionally substituted with hydroxy, alkoxy or fluoro;

R^3 is aryl selected from phenyl, indanyl and naphthyl; heteroaryl selected from benzothienyl, benzofuryl, thienyl, furyl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, and quinolyl; or

cycloalkyl having from three to seven carbon atoms, wherein one of said carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; wherein each of said aryl and heteroaryl groups may optionally be substituted with one or more substituents, and said (C_3-C_7)cycloalkyl may optionally be substituted with one or two substituents, said substituents being independently selected from halo, nitro, (C_1-C_{10})alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10})alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, amino, (C_1-C_6)-alkylamino, di(C_1-C_6)alkylamino, $-\overset{O}{\overset{\|}{C}}NH-(C_1-C_6)$alkyl, (C_1-C_6)alkyl$-\overset{O}{\overset{\|}{C}}-NH-(C_1-C_6)$alkyl, phenyl, hydroxy, $-NH\overset{O}{\overset{\|}{C}}H$, $-NH\overset{O}{\overset{\|}{C}}-(C_1-C_6)$alkyl, hydroxy$(C_1-C_6)$alkyl, and (C_1-C_6)alkoxy(C_1-C_6)alkyl;

R^6 is a functionality selected from hydrogen, (C_1-C_6)straight or branched alkyl, (C_3-C_7)cycloalkyl wherein one of the carbon atoms may optionally be replaced by nitrogen, oxygen or sulfur; aryl selected from biphenyl, phenyl, indanyl and naphthyl; heteroaryl selected from benzothienyl, thienyl, furyl, benzofuryl, pyridyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl and quinolyl; phenyl(C_2-C_6)alkyl, benzhydryl and benzyl, wherein each of said aryl and heteroaryl groups and the phenyl moieties of said benzyl, phenyl(C_2-C_6)alkyl and benzhydryl may optionally be substituted with one or more substituents independently selected from halo, nitro, (C_1-C_{10})alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10})alkoxy optionally substituted with from one to three fluorine atoms, amino, hydroxy(C_1-C_6)alkyl, (C_1-C_6)alkoxy(C_1-C_6)alkyl, (C_1-C_6)-alkylamino, (C_1-C_6)alkyl$-O-\overset{O}{\overset{\|}{C}}-$, (C_1-C_6)alkyl$-O-\overset{O}{\overset{\|}{C}}-$


(C1-C6)alkyl, (C1-C6)alkyl-C-O-, (C1-C6)alkyl-C-
(C1-C6)alkyl-O-, (C1-C6)alkyl-C-, (C1-C6)alkyl-C-
(C1-C6)alkyl-, di-(C1-C6)alkylamino, -CNH-(C1-C6)alkyl,(C1-C6)-
alkyl-C-NH-(C1-C6)alkyl, -NHCH and -NHC-(C1-C6)alkyl; and
wherein one of the phenyl moieties of said benzhydryl may
optionally be replaced by naphthyl, thienyl, furyl or
pyridyl;
R7 is hydrogen, phenyl or (C1-C6)alkyl;
or R6 and R7, together with the carbon to which they are
attached, form a saturated carbocyclic ring having from 3 to
7 carbon atoms wherein one of said carbon atoms may
optionally be replaced by oxygen, nitrogen or sulfur;
R8 may be attached to any atom of the nitrogen
containing ring having an available bonding site and R9 may
be attached to any atom of the (CH2)z containing ring having
an available bonding site or to any carbon atom of the
nitrogen containing ring having an available bonding site;
R8 and R9 are independently selected from hydrogen,
hydroxy, halo, amino, oxo (=O), cyano, hydroxy-(C1-C6)alkyl,
(C1-C6)alkoxy-(C1-C6)alkyl, (C1-C6)alkylamino,
di-(C1-C6)alkylamino, (C1-C6)alkoxy,
(C1-C6)alkyl-O-C-, (C1-C6)alkyl-O-C-(C1-C6)alkyl,
(C1-C6)alkyl-C-O-, (C1-C6)alkyl-C-(C1-C6)alkyl-O-,

(C_1-C_6)alkyl-$\overset{O}{\overset{\|}{C}}$-, (C_1-C_6)alkyl-$\overset{O}{\overset{\|}{C}}$-$(C_1-C_6)$alkyl-, and the functionalities set forth in the definition of R^6;

A is selected from the group consisting of CH_2, nitrogen, oxygen, sulfur and carbonyl;

G is nitrogen, oxygen or sulfur;

R^{10} is a monocyclic or bicyclic heterocycle selected from the group consisting of pyrimidinyl, benzoxazolyl, 2,3-dihydro-3-oxobenzisosulfonazol-2-yl, morpholin-1-yl, thiomorpholin-1-yl, benzofuranyl, benzothienyl, indolyl, isoindolyl, isoquinolinyl, furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, or thienyl groups of the formulae



wherein B and D are selected from carbon, oxygen, and nitrogen, and at least one of B and D is other than carbon; E is carbon or nitrogen; n is an integer from 1 to 5; and any one of the carbons of the $(CH_2)_n$ or $(CH_2)_{n+1}$ may be optionally substituted with (C_1-C_6)alkyl or (C_2-C_6) spiroalkyl, and either any two of the carbon atoms of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may be bridged by a one or two carbon atom linkage, or any one pair of adjacent carbons of said $(CH_2)_n$ and $(CH_2)_{n+1}$ may form, together with from one to three carbon atoms that are not members of the carbonyl containing ring, a (C_3-C_5) fused carbocyclic ring;

R^{11} is oximino (=NOH) or one of the functionalities set forth in any of the definitions of R^6, R^8 and R^9; and

with the proviso that (a) neither R^8, R^9, R^{10} nor R^{11} can form, together with the carbon to which it is attached, a ring with R^7, (b) when z is other than zero R^9 must be attached to the $(CH_2)_z$ containing ring and R^8 and R^9 cannot be

attached to the same carbon atom, (c) when both z is zero and R^8 and R^9 are attached to the same carbon atom, then either each of R^8 and R^9 is independently selected from hydrogen, fluoro (C_1-C_6)alkyl, hydroxy-(C_1-C_6)alkyl, and (C_1-C_6)alkoxy-(C_1-C_6)alkyl; or R^8 and R^9, together with the carbon to which they are attached, form a (C_3-C_6)saturated carbocyclic ring that forms a spiro compound with the nitrogen containing ring to which they are attached, (d) when A is nitrogen, sulfur or oxygen, m is greater than one, (e) when A is CH_2 or carbonyl, R^{10} cannot be furyl, pyridyl, isothiazolyl, oxazolyl, triazolyl, tetrazolyl, quinolyl, thiazolyl, or thienyl, (f) when w is other than zero, y is zero, the sum of w and z is less than 7,

x is an integer from 0 to 2,

z is an integer from 1 to 4, and wherein the ring containing $(CH_2)_z$ is a saturated ring wherein no carbon atom may be replaced by oxygen, sulfur or nitrogen, and wherein R^8 is optionally only a substituent on one of the carbon atoms of said $(CH_2)_z$.

2. A compound according to claim 1 wherein z is zero, G is nitrogen and R^9 is attached to the ring to which R^6 and R^7 are attached.

3. A compound according to claim 1 wherein m is an integer from 4 to 6; G is nitrogen; R^3 is phenyl, optionally substituted with one or two substituents, said substituents being independently selected from halo, nitro, (C_1-C_{10}) alkyl optionally substituted with from one to three fluorine atoms, (C_1-C_{10}) alkoxy optionally substituted with from one to three fluorine atoms, trifluoromethyl, amino, (C_1-C_6)-alkylamino, di(C_1-C_6)alkylamino, $-\overset{O}{\overset{\|}{C}}NH-(C_1-C_6)$alkyl, $-(C_1-C_6)alkyl-\overset{O}{\overset{\|}{C}}-NH-(C_1-C_6)$alkyl, phenyl, hydroxy, $-NH\overset{O}{\overset{\|}{C}}H$, $-NH\overset{O}{\overset{\|}{C}}-(C_1-C_6)$alkyl, hydroxy$(C_1-C_6)$alkyl, and (C_1-C_6)alkoxy(C_1-C_6)alkyl; R^6 is phenyl; R^7 is hydrogen; and R^1 is hydrogen.

4. A compound according to claim 3 wherein x is an integer from zero to two; w, y and z are zero; and R^1, R^8, R^9 and R^{11} are hydrogen.

5. A compound according to claim 1 wherein said compound is selected from (2S,3S)-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(thiazol-2-yl)aminobutyl]piperidine;

(2S,3S)-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(pyrimidin-2-yl)aminobutyl]piperidine;

cis-1-[4-(benzoxazol-2-yl)aminobutyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

(2S,3S)-1-[2,3-(dihydro-3-oxobenzisosulfonazol-2-yl)butyl]-3-(2-methoxybenzyl)amino-2-phenylpiperidine;

cis-3-(2-methoxybenzyl)amino-2-phenyl-1-[4-(succinimido-1-yl)butyl]piperidine; and

(2S,3S)-1-(5,6-carbonyldioxyhexyl)-3-(2-methoxybenzyl)amino-2-phenylpiperidine.

6. A pharmaceutical composition for treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), reflux gastroesophogal disease, hypertension anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising an amount of a compound according to

claim 1 effective in preventing or treating such condition and a pharmaceutically acceptable carrier.

7. A method of treating or preventing a condition selected from the group consisting of inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), reflux gastroesophogal disease, hypertension, anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis in a mammal, including a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1 effective in preventing or treating such condition.

8. A pharmaceutical composition for antagonizing the effects of substance P in a mammal, comprising a substance P antagonizing effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

9. A method of antagonizing the effects of substance P in a mammal, comprising administering to said mammal a substance P antagonizing effective amount of a compound according to claim 1.

10. A pharmaceutical composition for treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound according to claim 1 effective in

antagonizing the effect of substance P at its receptor site and a pharmaceutically acceptable carrier.

11. A method of treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, effective in antagonizing the effect of substance P at its receptor site.

12. A pharmaceutical composition for treating or preventing a condition in a mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising an amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition, and a pharmaceutically acceptable carrier.

13. A method of treating or preventing a condition in mammal, the treatment or prevention of which is effected or facilitated by a decrease in substance P mediated neurotransmission, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to claim 1 effective in treating or preventing such condition.

14. A pharmaceutical composition for treating or preventing urinary incontinence in a mammal, comprising an amount of a compound according to formula I wherein G is oxygen or sulfur effective in preventing or treating such condition and a pharmaceutically acceptable carrier.

15. A method of treating or preventing urinary incontinence in a mammal, comprising administering to a mammal in need of such treatment or prevention an amount of a compound according to formula I wherein G is oxygen or sulfur effective in preventing or treating such condition.

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 93/05077

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)[6]

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 C07D401/06; C07D401/12; C07D405/06; C07D409/06
C07D413/12; C07D417/12; A61K31/445

II. FIELDS SEARCHED

Minimum Documentation Searched[7]

Classification System	Classification Symbols
Int.Cl. 5	C07D

Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched[8]

III. DOCUMENTS CONSIDERED TO BE RELEVANT[9]

Category °	Citation of Document, [11] with indication, where appropriate, of the relevant passages [12]	Relevant to Claim No.[13]
P,A	WO,A,9 300 330 (PFIZER INC.) 7 January 1993 see the whole document & US910 717 943 21 June 1991 cited in the application	1-15
P,A	WO,A,9 300 331 (PFIZER INC.) 7 January 1993 see the whole document & US910 717 943 20 June 1991 cited in the application	1-15

-/--

° Special categories of cited documents : [10]

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report
14 SEPTEMBER 1993	21. 09. 93
International Searching Authority	**Signature of Authorized Officer**
EUROPEAN PATENT OFFICE	Bernd Kissler

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO,A,9 206 079 (PFIZER INC.) 16 April 1992 * see Example 3 * & US900 590 423 28 September 1990 cited in the application	1-15
X	EP,A,0 436 334 (PFIZER) 10 July 1991 see claim 1, page 57, lines 9-15 and page 58, line 32 see example 84	1-4,6,8, 10,12,14

INTERNATIONAL SEARCH REPORT

ternational application No.

PCT/US 93/05077

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although Claims 7,9,11,13,15 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searches without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM *PCT/ISA/*

Lack of conciseness

The definition of the following substituent(s) is too general and/or encompasses too broad a range of totally different chemical groups, only partly supported by examples given in the descriptive part of the application:

R1, R3, R6, R7, R8, R9, R10, R11, w, x, y, z, m.

The number of theoretically conceivable compounds resulting from the combination of all claimed substituents of above list precludes a comprehensive search. Guided by the spirit of the application and the inventive concept as disclosed in the descriptive part of the present application the search has been limited to the following case(s):

3-Benzylamino-2-phenyl-subst. piperidines.

Guidelines Exam. Part B, Chapt. III, 3.6, 3.7)

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

US 9305077
SA 75563

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 14/09/93

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9300330	07-01-93	AU-A-	2188992	25-01-93
WO-A-9300331	07-01-93	AU-A-	1889392	25-01-93
		CN-A-	1067655	06-01-93
WO-A-9206079	16-04-92	AU-A-	8746391	28-04-92
		CA-A-	2089736	29-03-92
		CN-A-	1060285	15-04-92
		EP-A-	0550635	14-07-93
EP-A-0436334	10-07-91	WO-A-	9109844	11-07-91
		EP-A-	0558156	01-09-93